The UK and US have hammered out a important bilateral deal that will keep zero levies on UK pharmaceutical products going into the American market.
The Terms of the Pact
Under the terms of the agreement, the UK has agreed to increase funding on medicines through the NHS. This move guarantees that duties on these key exports will stay at nothing for a period of the next three years.
This agreement follows recent warnings to hike tariffs on branded drug imports, with potential rates mentioned as high as double the cost.
"This agreement with the Britain bolsters the international landscape for cutting-edge drugs and brings long-overdue balance to U.S.–U.K. medicine commerce," an announcement said.
Economic Significance
Drugs represent one of the Britain's biggest exports to the America, which is by far the biggest market for major British pharmaceutical firms.
Export figures reveal that in the one-year period to the end of September, the UK sold medicines totaling billions to the US. This value made up 17.4% of British export trade in that period.
"This guarantee protects jobs, boosts investment and facilitates the UK to establish itself as a worldwide center for biotech and pharma," a minister commented.
Specific British Pledges
The agreement entails several key commitments from the United Kingdom:
- Price Threshold Increase: The UK will raise the price threshold at which it deems new treatments to be prohibitively costly by 25%.
- Increased NHS Spending: There is a target to double overall health service expenditure on drugs from 0.3% of GDP to 0.6 percent over the coming ten years.
- Payback Limit: The percentage manufacturers must refund to the NHS to prevent overspending will be limited at fifteen percent. In the past, rebates exceeded 20%.
Recent Tensions
The pact takes place against a long-running dispute between the drug companies and the UK government over drug pricing and NHS adoption.
The disagreement were heightened by arguments that US patients were charged significantly more for the same drugs than people in the other developed nations.
Recently, several large pharmaceutical investments in the UK have been halted or abandoned, while multi-billion-dollar funding commitments have been directed toward projects in the United States.
The Science Minister acknowledged that the NHS must invest a greater share on drugs, noting that its spending on drugs had shrunk as a proportion of its overall budget over the past decade.
